REPCF Live signaler | Maksimer profitt med Getagraph.com

Live Chart Being Loaded With Signals

Commentary (15 mar 2024 @ 16:20):

Stats
Dagens volum	550.00
Gjennomsnittsvolum	2 462.00
Markedsverdi	2.78M
EPS	$-0.0133 ( 2023-10-23 )
Neste inntjeningsdato	( $0 ) 2024-05-30
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.28
ATR14	$0 (0.00%)

RepliCel Life Sciences Korrelasjon

10 Mest positive korrelasjoner

10 Mest negative korrelasjoner

Visste du det?

Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).

Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.

RepliCel Life Sciences Økonomi

Annual	2022
Omsetning:	$353 735
Bruttogevinst:	$353 735 (100.00 %)
EPS:	$-0.0341

FY	2022
Omsetning:	$353 735
Bruttogevinst:	$353 735 (100.00 %)
EPS:	$-0.0341

FY	2021
Omsetning:	$353 735
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.151

FY	2020
Omsetning:	$353 735
Bruttogevinst:	$0.00 (0.00 %)
EPS:	$-0.0600

Financial Reports:

No articles found.

RepliCel Life Sciences

RepliCel Life Sciences Inc., a regenerative medicine company, focuses on developing autologous cell therapies that treat functional cellular deficits. Its treatments use autologous cell therapy, which isolates an individual's own cells from harvested tissues and growing more in controlled conditions in a laboratory. The company's product candidates include RCT-01 for the treatment of chronic tendinosis; RCS-01 to treat aging and sun damaged skin; and RCH-01 for the treatment of hair loss. It is also developing RCI-02, a dermal injection device. The company has a collaboration and technology transfer agreement with YOFOTO (China) Health Industry Co. Ltd. for establishing a clinical research program to develop and commercialize RCS-01 and RCT-01; and collaboration and technology transfer agreement with Shiseido Company, Limited for establishing a clinical research program for RCH-01. It also has a collaboration research project agreement with the University of British Columbia to build a hair follicle cell data map. RepliCel Life Sciences Inc. is headquartered in Vancouver, Canada.